Orrick-Led Ipsen To Buy US Cancer Biz For Up To $1.75B
French biopharmaceutical company Ipsen said Monday that it has agreed to acquire cancer-focused pharma business Kartos Therapeutics Inc. for up to $1.75 billion to expand its blood oncology drugs portfolio....To view the full article, register now.
Already a subscriber? Click here to view full article